The brokerage firm Motilal Oswal is optimistic about this pharma stock and expects it to deliver strong returns in the coming quarters. The brokerage has maintained a ‘Buy’ rating with a target price of Rs 2,310. This translates to an upside potential of nearly 17% from current market levels.

The stock in focus is Gland Pharma , which, according to the brokerage report, posted a mixed performance in the September quarter but continues to hold a strong product pipeline and upcoming capacity expansion.

Let’s take a look at the brokerage say on this stock –

Motilal Oswal on Gland Pharma: Margins dip, but outlook steady

According to the brokerage report, Gland Pharma’s revenue for the second quarter of FY26 was in line with estimates, but earnings before interest, tax, depreciation,

See Full Page